NmVac4-A/C/Y/W-135

NmVac4‑A/C/Y/W‑135 is the commercial designation for a meningococcal polysaccharide vaccine that targets four serogroups (A, C, Y, and W‑135) of the bacterium Neisseria meningitidis, the principal cause of meningococcal meningitis. The vaccine consists of purified capsular polysaccharides from each of the four serogroups, which are intended to elicit protective antibodies against infection.

Clinical Evaluation

• Safety and Immunogenicity (Polysaccharide Formulation) – Early clinical trials evaluated the vaccine’s ability to generate serogroup‑specific antibodies and recorded an acceptable safety profile, with adverse events generally limited to mild injection‑site reactions.
• Conjugate Variant (NmVac4‑A/C/Y/W‑135‑DT) – Subsequent studies investigated a conjugate formulation in which the polysaccharides are linked to diphtheria toxoid (DT). Phase II trials (e.g., NCT01482052 and NCT01897402) compared the conjugate vaccine to the licensed polysaccharide product, focusing on antibody titers and safety outcomes. Results indicated enhanced immunogenicity, particularly in younger age groups, while maintaining a comparable safety record.

Regulatory Status

Publicly available sources do not indicate that NmVac4‑A/C/Y/W‑135 has received widespread regulatory approval (e.g., FDA, EMA). Information on market authorization, manufacturing companies, or commercial distribution is limited.

Usage Context

The vaccine is designed for prophylactic immunization against meningococcal disease caused by the four targeted serogroups. It may be considered in settings where these serogroups predominate, such as certain regions of Africa and Asia, or for travelers to endemic areas. The conjugate variant aims to improve durability of the immune response and offer better protection in infants and toddlers, who respond less robustly to plain polysaccharide vaccines.

References

1. Wikipedia entry for NmVac4‑A/C/Y/W‑135 – https://en.wikipedia.org/wiki/NmVac4-A/C/Y/W-135
2. ClinicalTrials.gov, “Safety Study of Group A, C, Y & W‑135 Meningococcal Vaccine (NmVac4‑A/C/Y/W‑135‑DT)” – https://www.smartpatients.com/trials/NCT01482052
3. ClinicalTrials.gov, “Immunogenicity and Safety of Group A, C, Y & W‑135 Meningococcal Vaccine (NmVac4‑A/C/Y/W‑135‑DT)” – https://clinicaltrials.gov/study/NCT01897402